Lv1
40 积分 2025-11-30 加入
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
27天前
已完结
First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study
28天前
已完结
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States
28天前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
28天前
已完结
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective
3个月前
已完结
Cost-Utility Analysis of Durvalumab and Tremelimumab Versus Best Supportive Care in Refractory Metastatic Colorectal Cancer
3个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
4个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
